SBP GROUP (01177): Latest research results for TQ-A3334 "TLR7 agonist" and Bepirovirsen "ASO" will be presented at the 2026 AASLD
China Biopharmaceutical (01177) announced that a clinical study result of TQ-A3334 (TLR7 agonist), a National Class 1 innovative drug independently developed by the Company's subsidiary Chia Tai Tianqing Pharmaceutical Group Co., Ltd. (Chia Tai Tianqing), has been selected as a late-breaking abstract (LBA) for the 2026 Annual Meeting of the American Association for the Study of Liver Diseases (AASLD) and will be presented as an oral presentation; Bepirovirsen (ASO), a strategic collaboration product between Chia Tai Tianqing and GlaxoSmithKline (GSK), has been selected for 2 oral presentations and 8 poster presentations (including 1 distinguished poster).
SBP GROUP (01177) announced that a clinical study result for TQ-A3334 (TLR7 agonist), a National Class 1 innovative drug independently developed by the Company's subsidiary Chia Tai Tianqing Pharmaceutical Group Co., Ltd. (Chia Tai Tianqing), has been selected as a late-breaking abstract (LBA) at the 2026 Annual Meeting of the American Association for the Study of Liver Diseases (AASLD) and will be presented as an oral presentation; Bepirovirsen (ASO), a strategic collaboration product between Chia Tai Tianqing and GlaxoSmithKline (GSK), has been selected for 2 oral presentations and 8 poster presentations (including 1 distinguished poster).
Related Articles
7ROAD (00797) repurchased 150,000 shares for HKD 153,000 on October 14.
TIANYU SEMI (02658) repurchased 41,000 shares for HK$1,999,300 on October 14.
ASML Holding NV ADR (ASML.US) earnings validate EUV demand; UBS Group AG expects earnings upgrades over the next two years.
7ROAD (00797) repurchased 150,000 shares for HKD 153,000 on October 14.
TIANYU SEMI (02658) repurchased 41,000 shares for HK$1,999,300 on October 14.
ASML Holding NV ADR (ASML.US) earnings validate EUV demand; UBS Group AG expects earnings upgrades over the next two years.
